Linked Life Data

15508087

Source:http://linkedlifedata.com/resource/pubmed/id/15508087

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5 Suppl 1
pubmed:dateCreated
2004-10-27
pubmed:abstractText
The hallmarks of hepatocellular carcinoma (HCC) are that it is identified clinically at an advanced stage and usually together with cirrhosis. Surgical resection has been considered the optimal treatment approach, but only a small proportion of patients qualify for surgery, and there is a high rate of recurrence. Approaches to prevent recurrence have included chemoembolization before and neoadjuvant therapy after surgery, neither of which has proven to be beneficial. Liver transplantation has been successful in treating limited-stage HCC, affecting cure of both the tumor and underlying cirrhosis. However, only a minority of patients with HCC qualify for transplantation. Recently, chemoembolization has been shown to prolong survival in selected patients who do not qualify for transplantation or resection. Other innovative, relatively noninvasive local ablative therapies have been introduced and have been shown to be effective in reducing tumor size but not in prolonging survival. Standard chemotherapy is poorly tolerated in patients who do not qualify for resection. Both doxorubicin and cisplatin are frequently used, but overall response rates are low, and neither seems to prolong survival. Prospective, randomized controlled trials using current therapies are needed to better define optimal management of this important tumor. Most needed, however, are new therapeutic agents that are effective against HCC, are noncytotoxic, and are tolerated by the typical patient with underlying cirrhosis. Newly emerging agents with promise include 90 Y microspheres, antiangiogenesis agents, inhibitors of growth factors and their receptors, and K vitamins.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0016-5085
pubmed:author
pubmed:issnType
Print
pubmed:volume
127
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S218-24
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Hepatocellular carcinoma: current management and future trends.
pubmed:affiliation
Liver Cancer Center, Starzl Transplantation Institute, University of Pittsburgh Medical Center, BST, E 1552, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA. carrbi@upmc.edu
pubmed:publicationType
Journal Article, Review